Emerging Role of Weekly Topotecan in Recurrent Small Cell Lung Cancer

Emerging Role of Weekly Topotecan in Recurrent Small Cell Lung Cancer John R. Eckardt Oncologist 2004; 9: 25-32 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in lung cancer and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Identify the limitations of the established 5-day topotecan administration schedule in treating patients with recurrent SCLC. Explain the rationale for the use of weekly topotecan regimens in the recurrent SCLC setting. Discuss the efficacy and safety results from studies of weekly topotecan regimens in SCLC. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Dec. 22, 2004 Most Recent Review: Dec. 22, 2004* Most Recent Update: Dec. 22, 2004 Date Credit Expires: Apr. 10, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.